<DOC>
	<DOCNO>NCT00163241</DOCNO>
	<brief_summary>Objectives study : Primary : Assess ability continuous treatment celecoxib 200 mg versus placebo administer daily ( QD ) 24 month slow disease progression assess radiographically subject osteoarthritis ( OA ) hipSecondary : Assess ability continuous treatment celecoxib 200 mg versus placebo administer QD 24 month treat disease sign symptoms subject OA hip.Evaluate ability continuous 24-month intake celecoxib 200 mg QD versus placebo reduce number subject eligible hip replacement accord investigator.Evaluate tolerability safety continuous 24-month intake celecoxib 200 mg QD versus placebo subject OA hip .</brief_summary>
	<brief_title>Effect Of Celecoxib On Hip Osteoarthritis ( OA ) Progression</brief_title>
	<detailed_description>The study terminate 19 January 2006 , prematurely , result low enrollment Safety concern lead decision terminate study .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>The subject 50 year age old . If subject female childbearing potential , less 2 year postmenopausal , must use adequate contraception last menses use adequate contraception study , lactate , negative urine pregnancy test within 24 hour prior receive first dose study medication . Women less two year postmenopausal consider childbearing potential purpose study . The subject diagnose OA hip define American College Rheumatology ( ACR ) criterion ( see Appendix B ) The subject symptomatic OA , define presence daily hip pain least 1 month ( necessarily continuously ) 2 month prior screen visit . The subject hip pain &gt; equal 3 &lt; equal 9 10point Visual Numerical Scale ( VNS ) index hip . Subjects OA knee associate OA hip include provided knee OA pain intensity inferior hip 's one knee surgery expect study . Subjects functional class I , II III accord Steinbrocker criterion ( see Appendix C ) . The subject eligible pharmacologic treatment control arthritis symptom . The subject provide write informed consent undergo study procedure . Bilateral hip OA contralateral hip severe symptomatically radiologically index hip . The subject evidence secondary hip OA . Septic arthritis Systemic local inflammatory joint disease ( e.g . psoriatic arthritis , spondylarthropathy , systemic lupus erythematosus , etc . ) Gout Recurrent episode pseudogout Paget 's disease Articular fracture Ochronosis Acromegaly Haemochromatosis Wilson 's disease Primary osteochondromatosis Osteonecrosis Slipped Capital Femoral Epiphysis ( SCFE ) The subject concomitant inflammatory rheumatic condition , may interfere assessment OA , acute joint trauma index hip . The subject receive oral , intramuscular , intravenous , soft tissue injection corticosteroid within 4 week prior screen visit . The subject receive intraarticular injection corticosteroid hyaluronic acid index hip within 12 week prior screen visit . The subject receive diacerein , chondroitin sulfate , glucosamine sulfate , doxycycline avocado/soybean unsaponifiables within 12 week prior screen visit . Arthroscopy corrective surgery index hip perform . Arthroscopy corrective surgery contralateral hip perform within 6 month prior screen visit . Total replacement contralateral hip joint perform within 6 month prior screen visit . The subject felt require hip arthroplasty investigator screen visit . The subject active malignancy type . Subjects history basal cell carcinoma successfully treat acceptable . Subjects history malignancy successfully treat evidence recurrence least 5 year study also acceptable . The subject diagnose treated esophageal , gastric , pyloric channel , duodenal ulceration within 30 day prior screen visit . The subject history recurrent ulceration active inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) , chronic acute renal hepatic disorder , significant coagulation defect , condition , investigator 's opinion might preclude use NSAIDs . The subject history intolerance paracetamol , opioids tramadol felt adequate nonantiinflammatory rescue analgesic regimen safely prescribe , history alcohol substance abuse . The subject know hypersensitivity celecoxib , demonstrate allergictype reaction sulfonamide , experience asthma , urticaria allergictype reaction take sulfonamide , aspirin ( acetylsalicylic acid [ ASA ] ) , lactose NSAIDs . The subject diagnose treated gastrointestinal bleeding within 30 day screen visit . The subject previously admit study . The subject likelihood require treatment study period drug permit study protocol ( see Section 9 `` Concomitant therapy '' ) . The subject severe disease , likely jeopardize plan completion study The subject abnormal baseline finding condition , , investigator 's judgment might increase risk subject decrease chance obtain satisfactory data achieve objective study . The subject literate French English unable accord investigator answer question . The subject receive investigational drug within 30 day prior screen visit . The subject history myocardial infarction , unstable angina , ischemic hemorrhagic stroke , transient ischemic attack , previous revascularization procedure coronary , carotid , cerebral , renal , aortic peripheral arterial vasculature . The subject congestive heart failure ( Class IIIV ) . The subject use aspirin , include low dose aspirin . The subject use antiplatelet agent ( ticlopidine , clopidogrel , dipyridamole ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>